Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis

Biomedical Reports

Volumn 4, Issue 4, 2016, Pages 498-506

  Sun, Xue ^a,b   Yu, Wan Ying ^a,b   Ma, Wan Le ^a   Huang, Li Hua ^a   Yang, Guo Ping ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP4F2; Dose; Polymorphism; Thrombosis; Warfarin

Indexed keywords

WARFARIN;

ARTICLE; ASIAN; COMPARATIVE STUDY; CYP4F2 GENE; DATA EXTRACTION; DNA POLYMORPHISM; DRUG MEGADOSE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAINTENANCE DRUG DOSE; META ANALYSIS; PUBLISHING; QUALITY CONTROL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84989889458     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.599     Document Type: Article

References (35)

1. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, et al; International Warfarin Pharmacogenetics Consortium: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-764, 2009.
2. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr and Linder MW: Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 53: 1199-1205, 2007.
3. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, et al: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84: 326-331, 2008.
4. Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, Otsu K, Kouno Y, Tanabe T, Masunaga Y, et al: Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 65: 1097-1103, 2009.
5. Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdrè L, Frascaro M and Palareti G: A new warfarin dosing algorithm including VKORC1 3730 G>A polymorphism: Comparison with results obtained by other published algorithms. Eur J Clin Pharmacol 68: 1167-1174, 2012.
6. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, et al: Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients. Pharmacogenet Genomics 19: 226-234, 2009.
7. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE and Stricker BH: A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 18: 3758-3768, 2009.
8. McDonald MG, Rieder MJ, Nakano M, Hsia CK and Rettie AE: CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75: 1337-1346, 2009.
9. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, et al: CYP4F2 genetic variant alters required warfarin dose. Blood 111: 4106-4112, 2008.
10. Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, et al: Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10: 1905-1913, 2009.
11. Liang R, Li L, Li C, Gao Y, Liu W, Hu D and Sun Y: Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis 34: 120-125, 2012.
12. Li JH, Ma GG, Zhu SQ, Yan H, Wu YB and Xu JJ: Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients. J Cardiothorac Surg 7: 97, 2012.
13. Liang Y, Chen Z, Guo G, Dong X, Wu C, Li H, Wang T and Xu B: Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genet Test Mol Biomarkers 17: 932-936, 2013.
14. Li S, Zou Y, Wang X, Huang X, Sun Y, Wang Y, Dong L and Jiang H: Warfarin dosage response related pharmacogenetics in Chinese population. PLoS One 10: e0116463, 2015.
15. Zhuang W, Wen W, Xuan B, Chen Y, Cao Y, Sun Z and Ma J: Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients. Blood Coagul Fibrinolysis 26: 167-174, 2015.
16. Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, et al: Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: Systematic review and meta-analysis. Clin Pharmacol Ther 92: 746-756, 2012.
17. Liang R, Wang C, Zhao H, Huang J, Hu D and Sun Y: Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res 130: 38-44, 2012.
18. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O’Brien TR, et al: Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156: 300-310, 2002.
19. Lindh JD, Holm L, Andersson ML and Rane A: Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol 65: 365-375, 2009.
20. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, et al: CYP4F2 rs2108622: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 70: 234-240, 2010.
21. Lou Y, Han L, Li Y, Zhang X, Liu Z, Tang M, Yu H, Wang W, Xu J, Liu H and Li Y: Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 31: 367-371, 2014 (In Chinese).
22. Zhang HY, Luo WW, Fang HR, Yang XQ, Xu LH and Ma SM: Influence of VKORC1, CYP2C9, CYP4F2 and EPHX1 gene polymorphisms on warfarin dose. China Pharmacy 34: 3201-3205, 2012.
23. Zhu JR, Zhu YB, Xie DJ, Ye F and Tao YF: Effects of CYP4F2, CYP2C9 and VKORC1 genetic polymorphisms on maintenance dosage of warfarin in Chinese Han nationality patients with non-valve atrial fibrillation. China Pharmacy 44: 4161-4164, 2012.
24. Wang Z, Yang D, Li YL, et al: Influence of CYP4F2 gene polymorphisms on warfarin dose. Guangdong Medical Journal: 3091-3094, 2011.
25. Zhang YT, Liang X, Dong F, et al: Effect of CYP4F2 polymorphism on warfarin anticoagulant in Chinese population. Clinical Medication Journal: 41-59, 2014.
26. Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV and Adithan C: Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Eur J Clin Pharmacol 70: 47-56, 2014.
27. Özer M, Demirci Y, Hizel C, Sarikaya S, Karalti İ, Kaspar Ç, Alpan S and Genç E: Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Basic Clin Pharmacol Toxicol 112: 209-214, 2013.
28. Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, et al: Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thromb Res 135: 861-866, 2015.
29. Nakamura K, Obayashi K, Araki T, Aomori T, Fujita Y, Okada Y, Kurabayashi M, Hasegawa A, Ohmori S, Nakamura T, et al: CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther 37: 481-485, 2012.
30. Lee KE, Chang BC, Kim HO, Yoon IK, Lee NR, Park HY and Gwak HS: Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Ther Drug Monit 34: 275-282, 2012.
31. Singh O, Sandanaraj E, Subramanian K, Lee LH and Chowbay B: Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet 26: 130-136, 2011.
32. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M and Williamson PR: Influence of CYP2C9 and VKORC1 on patient response to warfarin: A systematic review and meta-analysis. PLoS One 7: e44064, 2012.
33. Yang L, Ge W, Yu F and Zhu H: Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta analysis. Thromb Res 125: e159-e166, 2010.
34. Jin B, Hong Y, Zhu J, Li Y and Shi HM: The impact of VKORC1-1639G>A genetic polymorphism upon warfarin dose requirement in different ethnic populations. Curr Med Res Opin 30: 1505-1511, 2014.
35. Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK and Beasley TM: Race influences warfarin dose changes associated with genetic factors. Blood 126: 539-545, 2015.